|
시장보고서
상품코드
2058362
코로나바이러스 치료제 시장 : 약물 종류별, 투여 경로별, 유통 채널별, 지역별Coronavirus Treatment Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
코로나바이러스 치료제 시장은 2026년에 248억 달러로 추정되며, 2033년까지 620억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 13.3%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 248억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 13.30% | 2033년 시장 규모 예측: | 620억 달러 |
신종 코로나바이러스 치료제란, 신종 코로나바이러스 치료에 사용되는 약물을 말합니다. 코로나바이러스 치료에는 코르티코스테로이드, 항바이러스제, 단클론항체, 키나아제 억제제 등 다양한 종류의 약물이 사용됩니다. 코로나바이러스 치료는 일반적으로 중증, 중등증, 경증과 같은 증상의 중증도에 따라 이루어집니다. 코로나바이러스의 일반적인 증상으로는 감기, 발열, 호흡 곤란, 두통, 복통 등이 있습니다.
시장 역학
주요 기업들은 세계 COVID-19 치료제 시장에서의 입지를 강화하기 위해 제품 승인 획득에 주력하고 있습니다. 예를 들어, 2020년 6월, 인도의 제약 회사인 글렌마크 파마슈티컬스 리미티드는 COVID-19 경증 및 중등증 환자를 대상으로 한 최초의 경구용 정제인 '파비풀'을 출시했습니다. 파비풀은 200mg 정제로 제공되며, 1정당 1달러로 책정되어 있습니다. 미국 내 환자 가격 : 34정들이 한 박스는 47.55달러입니다.
또한, 주요 기업들은 세계 COVID-19 치료제 시장에서의 입지를 강화하기 위해 이러한 계약 등 비유기적 전략에 주력하고 있습니다. 예를 들어, 2020년 9월, 인도의 제약 회사인 닥터 레디스 래버러토리즈(Dr. Reddy's Laboratories)는 인도 시장을 대상으로 '레딕스(Redyx)'라는 브랜드명으로 렘데시비르의 출시를 발표했습니다. COVID-19 치료제인 'Redyx'의 출시는 Dr Reddy's Laboratories와 Gilead Sciences Inc. 간의 라이선스 계약에 따른 것입니다. 이 계약을 통해 Dr Reddy's Laboratories는 인도를 포함한 127개국에서 렘데시비르를 COVID-19 잠재적 치료제로 등록, 제조 및 판매할 수 있는 권리를 부여받았습니다.
본 조사의 주요 특징
- 본 보고서는 전 세계 COVID-19 치료제 시장의 현황 및 향후 전망에 대해 조사하고 있습니다. 신종 코로나바이러스 치료제 시장은 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화되어 있습니다.
- 본 보고서는 전 세계 코로나바이러스 치료제 시장에 대한 상세한 분석을 바탕으로, 예측 기간(2026-2033년) 동안의 시장 규모 및 연평균 성장률(CAGR, %)을 제시하고 있습니다.
- 본 보고서는 각 부문별 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다. 또한, 시장 촉진요인, 시장 억제요인, 기회, 국가별 전망 및 주요 기업들이 채택하고 있는 경쟁 전략에 관한 귀중한 인사이트를 제공합니다.
- 본 보고서에서는 다음의 매개변수를 바탕으로 전 세계 코로나바이러스 치료제 시장의 주요 기업 개요을 작성했습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 지리적 확장, 주요 발전 사항 및 향후 계획입니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 보고서는 투자자, 제품 개발자 및 제조업체, 유통업체, 의료 기관, 연구 기관, 신규 진입 기업, 금융 애널리스트 등 해당 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 COVID-19 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정 과정에서 큰 도움을 받을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 코로나바이러스 치료제 시장 : 약물 종류별, 2021-2033년
제5장 세계의 코로나바이러스 치료제 시장 : 투여 경로별, 2021-2033년
제6장 세계의 코로나바이러스 치료제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 코로나바이러스 치료제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 참고문헌 및 조사 방법
KSM 26.06.19Coronavirus Treatment Drugs Market is estimated to be valued at USD 24.8 Bn in 2026 and is expected to reach USD 62 Bn by 2033, growing at a compound annual growth rate (CAGR) of 13.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 24.8 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.30% | 2033 Value Projection: | USD 62 Bn |
The coronavirus treatment drugs comprises therapeutics which are used for treatment of the novel coronavirus. There are various drug classes such as corticosteroids, anti-viral, monoclonal antibodies, Kinase inhibitors which can be used for treatment of the coronavirus. The coronavirus is generally treated depending on severity of symptoms such as severe, moderate and mild. The common symptoms of coronavirus are cold, fever, breathlessness, headache, and stomach pain.
Market Dynamics
Key players are focusing on obtaining product approvals in order to strengthen their position in the global coronavirus treatment drugs market. For instance, in June 2020, Glenmark Pharmaceuticals Limited, a pharmaceutical company in India, launched the first orally administered tablet, Fabiflu, for the treatment of patients suffering from mild and moderate symptoms of COVID-19. Fabiflu is available as a 200 mg tablet, has been priced at US$ 1 per tablet. A strip of 34 tablets will cost US$ 47.55 to the patients in India.
Furthermore, key companies are focusing on inorganic strategies such agreements in order to strengthen their position in the global coronavirus treatments drugs market. For instance, in September 2020, Dr Reddy's Laboratories, an Indian pharmaceutical company, announced the launch of Remdesivir under the brand name, Redyx, for the Indian market. The launch of Redyx for treatment for COVID-19 is because of licensing agreement of Dr Reddy Laboratories with Gilead Sciences Inc. which grants Dr Reddy's Laboratories the right to register, manufacture and sell Remdesivir, as a potential treatment for COVID-19 in 127 countries including India.
Key features of the study
- This report studies the current scenario as well as the future potential of the global coronavirus treatment drugs market. The market for coronavirus treatment drugs is segmented on the basis of drug class, route of administration, distribution channel, and region.
- This report provides in-depth analysis of the global coronavirus treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026-2033)
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by leading players.
- It profiles leading players in the global coronavirus treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
- The global coronavirus treatment drugs market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
- Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global coronavirus treatment drugs market.
Market Segmentation
- By Drug Class (Revenue, USD Bn, 2021-2033)
- Corticosteroids
- Anti-viral drugs
- Monoclonal Antibodies
- Kinase Inhibitors
- Others
- By Route of Administration (Revenue, USD Bn, 2021-2033)
- Oral
- Intravenous
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Serum Institute of India
- Pfizer Inc.
- AstraZeneca plc.
- Bharat Biotech International Limited
- Cadila Healthcare Limited
- Johnson & Johnson
- Moderna
- GlaxoSmithKline plc.
- CanSino Biologics
- Sinovac Biotech
- Novavax, Inc.
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc.
- Reddy's Laboratories
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Coronavirus Treatment Drugs Market, By Drug Class
- Global Coronavirus Treatment Drugs Market, By Route of Administration
- Global Coronavirus Treatment Drugs Market, By Distribution Channel
- Global Coronavirus Treatment Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Coronavirus Treatment Drugs Market, By Drug Class, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Anti-viral drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Kinase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Coronavirus Treatment Drugs Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Coronavirus Treatment Drugs Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Coronavirus Treatment Drugs Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Serum Institute of India
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bharat Biotech International Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cadila Healthcare Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Moderna
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CanSino Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sinovac Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novavax, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
